Key facts
- This page summarizes AI Biotechnology LLC's Form 3 filing for VYNE Therapeutics Inc. (VYNE).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Nov 2023, 08:30.
AI Biotechnology LLC - 01 Nov 2023 Form 3 Insider Report for VYNE Therapeutics Inc. (VYNE)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- VYNE
- Reported as of
- 01 Nov 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 13 Nov 2023, 08:30:21 UTC
- Next SEC filing
- 28 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alejandro Moreno for AI Biotechnology LLC
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
AI Biotechnology LLC filed Form 3 for VYNE Therapeutics Inc. (VYNE) on 13 Nov 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VYNE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,116,585
- Date
- 01 Nov 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VYNE
holding
Derivative
Warrant (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,792,448
- Exercise price
- $0.000100
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The securities reported are held directly by AI Biotechnology LLC ("AI Biotechnology") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AI Biotechnology. Each of the reporting persons (other than AI Biotechnology) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.
Footnote F2
Each pre-funded warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. The pre-funded warrants are not exercisable to the extent that the aggregate number of shares of Common Stock beneficially owned by AI Biotechnology immediately following such exercise would exceed 9.99%; provided, however, that AI Biotechnology may increase or decrease the beneficial ownership limitation by giving 60 days' notice to the Issuer, but not to exceed any percentage in excess of 19.99%.
SEC remarks
Exhibit List: Ex.24 - Power of Attorney